Cargando…

Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients

INTRODUCTION: Using mathematical modelling allows to select a treatment's regimen across infinite possibilities. Here, we report the phase I assessment of a new schedule for metronomic vinorelbine in treating refractory advanced NSCLC and mesothelioma patients. RESULTS: Overall, 13 patients wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barlesi, Fabrice, Imbs, Diane-Charlotte, Tomasini, Pascale, Greillier, Laurent, Galloux, Melissa, Testot-Ferry, Albane, Garcia, Mélanie, Elharrar, Xavier, Pelletier, Annick, André, Nicolas, Mascaux, Céline, Lacarelle, Bruno, Cheikh, Raouf El, Serre, Raphaël, Ciccolini, Joseph, Barbolosi, Dominique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564552/ https://www.ncbi.nlm.nih.gov/pubmed/28525370 http://dx.doi.org/10.18632/oncotarget.17562

Ejemplares similares

A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol
por: Elharrar, Xavier, et al.
Publicado: (2016)

Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non‐Small Cell Lung Carcinoma
por: Imbs, Diane‐Charlotte, et al.
Publicado: (2017)

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
por: Boyer, Arnaud, et al.
Publicado: (2018)

Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis
por: Mollard, Severine, et al.
Publicado: (2017)

Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer
por: Gouton, Etienne, et al.
Publicado: (2022)

Personalised medicine for nonsmall cell lung cancer
por: Mascaux, Céline, et al.
Publicado: (2017)

An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer
por: Pujol, Jean-Louis, et al.
Publicado: (2019)

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
por: Greillier, Laurent, et al.
Publicado: (2016)

Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data
por: Benzekry, Sébastien, et al.
Publicado: (2021)

MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors
por: Vicier, C., et al.
Publicado: (2022)

Immunologically effective dose: a practical model for immuno-radiotherapy
por: Serre, Raphaël, et al.
Publicado: (2018)

Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma
por: Qin, Rong-Sheng, et al.
Publicado: (2018)

Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study
por: Liu, Chien-Ting, et al.
Publicado: (2021)

Anti-tumor effects of low-dose metronomic vinorelbine in combination with alpelisib in breast cancer cells
por: Krajnak, Slavomir, et al.
Publicado: (2023)

Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients
por: Faivre, C, et al.
Publicado: (2017)

Cellular and molecular effects of metronomic vinorelbine and 4-O-deacetylvinorelbine on human umbilical vein endothelial cells
por: Biziota, Eirini, et al.
Publicado: (2016)

EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer
por: Tomasini, Pascale, et al.
Publicado: (2016)

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer
por: Travert, Camille, et al.
Publicado: (2019)

Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience
por: Rossi, David
Publicado: (2020)

Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases
por: Tomasini, Pascale, et al.
Publicado: (2019)

Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine – a Phase I trial
por: Guetz, Sylvia, et al.
Publicado: (2017)

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
por: Sørensen, J B, et al.
Publicado: (2008)

Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis
por: Gebbia, Vittorio, et al.
Publicado: (2020)

Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review
por: Chi, Yajing, et al.
Publicado: (2022)

Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer
por: Bilous, M., et al.
Publicado: (2019)

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study
por: Briasoulis, Evangelos, et al.
Publicado: (2013)

Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer
por: D'Ascanio, Michela, et al.
Publicado: (2018)

Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study
por: Cerrito, Maria Grazia, et al.
Publicado: (2018)

Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study
por: Cazzaniga, M. E., et al.
Publicado: (2014)

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
por: Adamo, Barbara, et al.
Publicado: (2019)

Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial
por: Wang, Zijing, et al.
Publicado: (2021)

Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study
por: Pepe, F. F., et al.
Publicado: (2022)

Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)
por: Camerini, Andrea, et al.
Publicado: (2015)

Metronomic vinorelbine: Anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition
por: MAVROEIDIS, L., et al.
Publicado: (2015)

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer
por: Chai, Yue, et al.
Publicado: (2023)

A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients
por: Becher, François, et al.
Publicado: (2017)

Validation of Neutrophil Count as An Algorithm-Based Predictive Factor of Progression-Free Survival in Patients with Metastatic Soft Tissue Sarcomas Treated with Trabectedin
por: de Nonneville, Alexandre, et al.
Publicado: (2019)

Metronomic chemotherapy
por: Maiti, Rituparna
Publicado: (2014)

Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021)

Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC
por: Ciccolini, Joseph, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_04bqve3nadaus10c00n9bsouv9